IN8bio (NASDAQ:INAB) Stock Price Down 2.8% – Time to Sell?

Posted by George Bondi on Jun 16th, 2026

IN8bio, Inc. (NASDAQ:INAB – Get Free Report)’s stock price traded down 2.8% during trading on Monday . The company traded as low as $1.39 and last traded at $1.39. 30,679 shares changed hands during trading, a decline of 54% from the average session volume of 66,706 shares. The stock had previously closed at $1.43.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

View Our Latest Analysis on IN8bio

IN8bio Stock Performance

The business has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.77. The stock has a market cap of $13.69 million, a price-to-earnings ratio of -0.53 and a beta of 0.19.

IN8bio (NASDAQ:INAB – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.33. On average, equities research analysts anticipate that IN8bio, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On IN8bio

Several hedge funds have recently made changes to their positions in INAB. Two Sigma Investments LP acquired a new stake in shares of IN8bio during the third quarter worth $107,000. Citadel Advisors LLC acquired a new stake in shares of IN8bio during the third quarter worth $54,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of IN8bio during the fourth quarter worth $56,000. Franklin Resources Inc. boosted its holdings in shares of IN8bio by 381.6% during the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares during the last quarter. Finally, HRT Financial LP acquired a new stake in shares of IN8bio during the fourth quarter worth $34,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

(Get Free Report)

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.